Search
Tetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Mixtures: Lidocaine and Tetracaine, Lidocaine and TetracaineCategories: Antipruritics and Local Anesthetics, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Categories: Antineoplastic and Immunomodulating AgentsProducts: COTELLIC FILM COATED TABLET 20MGSodium- and chloride-dependent glycine transporter 1
go.drugbank.com/bio_entities/BE0000940TransporterTargetHumansSodium- and chloride-dependent glycine transporter (PubMed:37962965, PubMed:8183239). Essential for regulating glycine concentrations at inhibitory glycinergic synapses
Polypeptides: Sodium- and chloride-dependent glycine transporter 1Troponin C, slow skeletal and cardiac muscles
go.drugbank.com/bio_entities/BE0001024TargetHumansTn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C.
Polypeptides: Troponin C, slow skeletal and cardiac musclesSodium- and chloride-dependent glycine transporter 2
go.drugbank.com/bio_entities/BE0002310TransporterTargetHumansSodium- and chloride-dependent glycine transporter (PubMed:10381548, PubMed:10606742, PubMed:16751771, PubMed:31370103, PubMed:9845349).
Polypeptides: Sodium- and chloride-dependent glycine transporter 2Signal transducer and activator of transcription 3
go.drugbank.com/bio_entities/BE0003462TargetHumansand IL6ST) (PubMed:9188471) … Following JAK/STAT signaling activation and as part of a complex with NFATC3 and NFATC4, binds to the alpha-beta E4 promoter region of CRYAB and activates transcription in cardiomyocytes (By similarity
Polypeptides: Signal transducer and activator of transcription 3Disintegrin and metalloproteinase domain-containing protein 17
go.drugbank.com/bio_entities/BE0003754TargetHumansMediates the proteolytic cleavage and shedding of FCGR3A upon NK cell stimulation, a mechanism that allows for increased NK cell motility and detachment from opsonized target cells. … and immunity (PubMed:24226769, PubMed:24227843, PubMed:28060820, PubMed:28923481, PubMed:38771644).
Polypeptides: Disintegrin and metalloproteinase domain-containing protein 17Macrophage scavenger receptor types I and II
go.drugbank.com/bio_entities/BE0010942TargetHumansRecognizes and internalizes modified forms of low-density lipoproteins including acetylated LDL (AcLDL) and oxidized LDL (OxLDL), thereby promoting cholesterol uptake and contributing to foam cell formation … Binds various pathogen-associated and damage-associated molecules, including bacterial cell wall components, apoptotic cell debris and polyanionic ligands, supporting macrophage clearance activity in innate
Polypeptides: Macrophage scavenger receptor types I and IISynonyms: Macrophage acetylated LDL receptor I and IICleavage and polyadenylation specificity factor subunit 3
go.drugbank.com/bio_entities/BE0021153TargetHumansand other factors to bring about cleavage and poly(A) addition. … Only required for the biogenesis of miR-290 and miR-96 from the pri-miR-290-295 and pri-miR-96-183 primary transcripts, respectively (By similarity)
Polypeptides: Cleavage and polyadenylation specificity factor subunit 3Synonyms: Cleavage and polyadenylation specificity factor 73 kDa subunitTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL